glp-1 microdosing perimenopause for Perimenopause: Why Lower Doses Might Be Better GLP-1 Weight Loss in Menopause:

There is a bipartisan legislative effort in the Senate that could help address this one component of federal oversight

Pure Medical Spa evaluates each patient individually to ensure GLP-1 therapy supports-not disrupts-an active lifestyle

Ready to Explore Microdosing

At the end of 2016, the Amgen team filed a patent (US20170275370A1) titled "Methods for Treating or Ameliorating Metabolic Disorders Using a GIPR Binding Protein in Combination with a GLP-1 Agonist." This reported the therapeutic potential of using an antibody targeting the GIPR in combination with a GLP-1 receptor agonist for the treatment of type 2 diabetes, obesity, dyslipidemia, elevated levels of glucose, increased insulin levels, and diabetic nephropathy

As an aside and earlier stage, Regeneron are interested in understanding obesity as a heterogeneous disease and, through the Regeneron Genetic Center, finding and developing novel genetic targets for obesity